[go: up one dir, main page]

EA200801826A1 - Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения - Google Patents

Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения

Info

Publication number
EA200801826A1
EA200801826A1 EA200801826A EA200801826A EA200801826A1 EA 200801826 A1 EA200801826 A1 EA 200801826A1 EA 200801826 A EA200801826 A EA 200801826A EA 200801826 A EA200801826 A EA 200801826A EA 200801826 A1 EA200801826 A1 EA 200801826A1
Authority
EA
Eurasian Patent Office
Prior art keywords
deuterated catecholamine
catecholamine derivatives
indicated compounds
medicines containing
compounds
Prior art date
Application number
EA200801826A
Other languages
English (en)
Other versions
EA017983B1 (ru
Inventor
Рудольф-Гизберт Алкен
Франк Шнайдер
Original Assignee
Бедс Фарма Гмбх Беролина Инновейтив Ресёч Энд Девелопмент Сёвисиз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бедс Фарма Гмбх Беролина Инновейтив Ресёч Энд Девелопмент Сёвисиз filed Critical Бедс Фарма Гмбх Беролина Инновейтив Ресёч Энд Девелопмент Сёвисиз
Publication of EA200801826A1 publication Critical patent/EA200801826A1/ru
Publication of EA017983B1 publication Critical patent/EA017983B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к дейтерированным производным катехоламина, а также к фармацевтическим средствам, содержащим эти соединения. В дополнение к этому изобретение относится к использованию дейтерированных производных катехоламина, а также их фармацевтически приемлемых солей и фармацевтических композиций, которые содержат эти соединения, также в комбинации с ингибиторами ферментов для лечения болезней, вызываемых недостатком допамина или болезней, которые основываются на нарушении передачи тирозина или нарушении тирозиндекарбоксилазы, а также других расстройств.
EA200801826A 2006-02-17 2007-02-16 Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения EA017983B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006008316 2006-02-17
PCT/EP2007/001555 WO2007093450A2 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds

Publications (2)

Publication Number Publication Date
EA200801826A1 true EA200801826A1 (ru) 2009-02-27
EA017983B1 EA017983B1 (ru) 2013-04-30

Family

ID=38236462

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801826A EA017983B1 (ru) 2006-02-17 2007-02-16 Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения

Country Status (24)

Country Link
US (2) USRE46555E1 (ru)
EP (2) EP3101001B1 (ru)
JP (1) JP5248331B2 (ru)
KR (1) KR101411422B1 (ru)
CN (1) CN101384545B (ru)
AU (1) AU2007214622B2 (ru)
BR (1) BRPI0708071A8 (ru)
CA (1) CA2642593C (ru)
CY (1) CY1117995T1 (ru)
DK (1) DK1991522T3 (ru)
EA (1) EA017983B1 (ru)
ES (1) ES2587368T3 (ru)
HR (1) HRP20161039T1 (ru)
HU (1) HUE028777T2 (ru)
IL (1) IL193102A (ru)
LT (1) LT1991522T (ru)
ME (1) ME02508B (ru)
PL (1) PL1991522T3 (ru)
PT (1) PT1991522T (ru)
RS (1) RS55142B1 (ru)
SI (1) SI1991522T1 (ru)
UA (1) UA97795C2 (ru)
WO (1) WO2007093450A2 (ru)
ZA (1) ZA200806568B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
NO2303330T3 (ru) 2008-06-06 2018-04-14
RU2509773C2 (ru) 2008-07-15 2014-03-20 Теракос, Инк. Дейтерированные бензилбензольные производные и способы применения
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9763904B2 (en) 2013-02-05 2017-09-19 Teva Pharmaceuticals International Gmbh Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds
WO2014122184A1 (en) 2013-02-05 2014-08-14 Cdrd Berolina Ab Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds
WO2014174425A2 (en) * 2013-04-24 2014-10-30 Mahesh Kandula Compositions and methods for the treatment of orthostasis and neurological diseases
EA201600093A1 (ru) * 2013-07-08 2016-08-31 Ауспекс Фармасьютикалс, Инк. Дигидроксифенильные нейромедиаторные соединения, композиции и способы
MX2016006622A (es) * 2013-11-22 2016-12-09 Auspex Pharmaceuticals Inc Metodos para tratar actividad muscular anormal.
AU2014357518A1 (en) 2013-12-03 2016-06-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
KR20160117596A (ko) 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
EP2918266A1 (en) 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
GB201420341D0 (en) * 2014-11-17 2014-12-31 Evolution Valves Ltd Valve arrangement
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
CN106343013A (zh) * 2015-07-19 2017-01-25 中国科学院上海有机化学研究所 一种粮食储存方法
CN105360267B (zh) * 2015-10-09 2017-11-10 青岛振坤食品机械有限公司 一种全自动穿串机
BR112018007118A2 (pt) 2015-10-09 2018-12-11 Teva Pharmaceuticals Int Gmbh método para tratar um distúrbio de deficiência de dopamina, método para melhorar o tempo motor ativo sem discinesia num paciente com doença de parkinson, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir o tempo motor inativo num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir flutuações de nível de dopamina estriatal num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina após um tratamento de longo prazo, composição farmacêutica e embalagem
CN105862897B (zh) * 2016-04-11 2018-01-16 江苏省华建建设股份有限公司 砂质泥岩地基浅基础原槽浇筑施工工法
EP3849533A4 (en) 2018-09-13 2022-06-22 University of Canberra Methods of inhibition
AU2019392924A1 (en) * 2018-12-06 2021-06-17 Senda Biosciences, Inc Quaternary ammonium salts as inhibitors of trimethylamine production

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699158A (en) 1969-08-25 1972-10-17 Merck & Co Inc Selective deuteration of tyrosine, aspartic and glutamic acids
DE2049807A1 (en) 1970-10-10 1972-04-13 Hartmeyer H Conversion of closed cell plastics foam to - open cell structure
DE2049115C3 (de) 1970-10-06 1981-07-30 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Tokyo Verwendung von Calcium-5-butylpicolinat und/oder Calcium-5-pentylpicolinat bei der Bekämpfung des Parkinsonismus mit 3-(3,4-Dihydroxyphenyl)-L-alanin (L-Dopa)
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
IT1226902B (it) 1988-07-12 1991-02-21 Mini Ricerca Scient Tecnolog Processo per la sintesi del levodopa
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
DE10261808A1 (de) 2002-12-19 2004-07-08 Turicum Drug Development Ag Verwendung von L-DOPA, seiner Derivate und diese Verbindungen enthaltender Arzneimittel zur Prophylaxe psychotischer Erkrankungen

Also Published As

Publication number Publication date
JP2009526799A (ja) 2009-07-23
BRPI0708071A2 (pt) 2011-05-17
EP3101001B1 (en) 2020-04-01
EA017983B1 (ru) 2013-04-30
KR20080106539A (ko) 2008-12-08
AU2007214622B2 (en) 2012-02-23
HRP20161039T1 (hr) 2016-11-04
DK1991522T3 (en) 2016-08-29
CN101384545B (zh) 2014-09-03
BRPI0708071A8 (pt) 2017-12-26
ES2587368T3 (es) 2016-10-24
PT1991522T (pt) 2016-08-23
RS55142B1 (sr) 2016-12-30
CA2642593A1 (en) 2007-08-23
US20090018191A1 (en) 2009-01-15
CA2642593C (en) 2014-11-04
WO2007093450A2 (en) 2007-08-23
IL193102A0 (en) 2009-02-11
LT1991522T (lt) 2016-09-26
EP1991522A2 (en) 2008-11-19
EP3101001A1 (en) 2016-12-07
PL1991522T3 (pl) 2017-07-31
US8247603B2 (en) 2012-08-21
ZA200806568B (en) 2009-07-29
WO2007093450A3 (en) 2007-09-27
USRE46555E1 (en) 2017-09-19
SI1991522T1 (sl) 2016-10-28
AU2007214622A1 (en) 2007-08-23
ME02508B (me) 2017-06-20
KR101411422B1 (ko) 2014-07-03
HUE028777T2 (en) 2017-01-30
JP5248331B2 (ja) 2013-07-31
EP1991522B1 (en) 2016-05-18
UA97795C2 (ru) 2012-03-26
CN101384545A (zh) 2009-03-11
CY1117995T1 (el) 2017-05-17
IL193102A (en) 2015-01-29

Similar Documents

Publication Publication Date Title
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
MX384206B (es) Formulaciones de inhibidores de dpp iv
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
EA200700909A1 (ru) Азаиндолкарбоксамиды
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

TC4A Change in name of a patent proprietor in a eurasian patent
PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU